TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive CMS, FDA Developing Process For Concurrent Therapy ApprovalsAACI To Honor Mary-Claire King, Sen. Sherrod Brown October 1, 2010
TCL Archive Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival January 31, 2014
